Margherita Ambrosini/LinkedIn
Jun 1, 2025, 06:00
Margherita Ambrosini Highlights ARMANI Trial Findings in HER2-Negative Gastric Cancer at ASCO 2025
Margherita Ambrosini, Medical Doctor, Oncology Clinical and Research Fellow at the Fondazione IRCCS National Cancer Institute in Milan, posted on LinkedIn:
“Switch maintenance with paclitaxel plus ramucirumab significantly improved key disease related symptoms and delayed clinical deterioration compared to continuation of oxaliplatin and fluoropyrimidine first line chemotherapy in patients with advanced HER2- gastric/gej cancer enrolled in the phase 3 ARMANI trial.
Pass by poster board 350 to discuss about it!”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20
Jun 2, 2025, 14:49
Jun 2, 2025, 13:13